nitroblue tetrazolium has been researched along with alitretinoin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujino, T; Inoue, K; Kanayasu-Toyoda, T; Nishimaki-Mogami, T; Ohno, Y; Oshizawa, T; Sato, Y; Sawada, J; Shudo, K; Suzuki, T; Yamaguchi, T | 1 |
1 other study(ies) available for nitroblue tetrazolium and alitretinoin
| Article | Year |
|---|---|
HX531, a retinoid X receptor antagonist, inhibited the 9-cis retinoic acid-induced binding with steroid receptor coactivator-1 as detected by surface plasmon resonance.
Topics: Alitretinoin; Benzoates; Biphenyl Compounds; CD11b Antigen; Cell Differentiation; Cell Proliferation; Histone Acetyltransferases; Nitroblue Tetrazolium; Nuclear Receptor Coactivator 1; Receptors, Formyl Peptide; Retinoid X Receptors; Surface Plasmon Resonance; Transcription Factors; Tretinoin | 2005 |